Impact of simple equation for estimating appendicular skeletal muscle mass in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
ASM, appendicular skeletal muscle mass
ASMI, appendicular skeletal muscle mass index
AWGS, Asian Working Group for Sarcopenia
Appendicular skeletal mass index
BIA, bioelectrical impedance analysis
CAD, coronary artery disease
CI, confidence interval
CKD, chronic kidney disease
CVD, cardiovascular deaths
Coronary artery disease
DXA, dual-energy X-ray absorptiometry
HR, hazard ratio
LVEF, left ventricular ejection fraction
MACE, major adverse cardiac events
PCI, percutaneous coronary intervention
Percutaneous coronary intervention
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
24
08
2022
revised:
24
11
2022
accepted:
09
12
2022
entrez:
22
12
2022
pubmed:
23
12
2022
medline:
23
12
2022
Statut:
epublish
Résumé
Sarcopenia, which is evaluated based on appendicular skeletal muscle mass (ASM) using dual-energy X-ray absorptiometry and bioelectrical impedance analysis, is a prognostic predictor for adverse outcomes in patients with coronary artery disease (CAD). However, a simple equation for estimating ASM is yet to be validated in clinical practice. We enrolled 2211 patients with CAD who underwent percutaneous coronary intervention at our hospital between 2010 and 2017. The mean age was 68 years and 81.5 % were men. Patients were divided into 2 groups based on each ASM index (ASMI): low; male < 7.3 and female < 5.0 and high; male ≥ 7.3 and female ≥ 5.0. ASM was calculated using the following equation: 0.193 × bodyweight + 0.107 × height - 4.157 × gender - 0.037 × age - 2.631. Primary endpoints were major adverse cardiac events (MACE, which includes cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for heart failure), and all-cause mortality. During the median follow-up period of 4.8 years, cumulative incidence of events were significantly higher in the low ASMI group. Cox proportional hazards model revealed that the low ASMI group had a significantly higher risk of primary endpoints than the high ASMI group (all-cause mortality; hazard ratio (HR): 2.13, 95 % confidence interval [CI]: 1.40-3.22, p < 0.001 and 4-point MACE; HR: 1.72, 95 % CI: 1.12-2.62, p = 0.01). Similar trends were observed after stratification by age of 65 years. Low ASMI, evaluated using the aforementioned equation, is an independent predictor of MACE and all-cause mortality in patients with CAD.
Sections du résumé
Background
UNASSIGNED
Sarcopenia, which is evaluated based on appendicular skeletal muscle mass (ASM) using dual-energy X-ray absorptiometry and bioelectrical impedance analysis, is a prognostic predictor for adverse outcomes in patients with coronary artery disease (CAD). However, a simple equation for estimating ASM is yet to be validated in clinical practice.
Methods
UNASSIGNED
We enrolled 2211 patients with CAD who underwent percutaneous coronary intervention at our hospital between 2010 and 2017. The mean age was 68 years and 81.5 % were men. Patients were divided into 2 groups based on each ASM index (ASMI): low; male < 7.3 and female < 5.0 and high; male ≥ 7.3 and female ≥ 5.0. ASM was calculated using the following equation: 0.193 × bodyweight + 0.107 × height - 4.157 × gender - 0.037 × age - 2.631. Primary endpoints were major adverse cardiac events (MACE, which includes cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for heart failure), and all-cause mortality.
Results
UNASSIGNED
During the median follow-up period of 4.8 years, cumulative incidence of events were significantly higher in the low ASMI group. Cox proportional hazards model revealed that the low ASMI group had a significantly higher risk of primary endpoints than the high ASMI group (all-cause mortality; hazard ratio (HR): 2.13, 95 % confidence interval [CI]: 1.40-3.22, p < 0.001 and 4-point MACE; HR: 1.72, 95 % CI: 1.12-2.62, p = 0.01). Similar trends were observed after stratification by age of 65 years.
Conclusion
UNASSIGNED
Low ASMI, evaluated using the aforementioned equation, is an independent predictor of MACE and all-cause mortality in patients with CAD.
Identifiants
pubmed: 36545275
doi: 10.1016/j.ijcha.2022.101163
pii: S2352-9067(22)00212-3
pmc: PMC9762183
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101163Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
N Engl J Med. 2015 Apr 2;372(14):1333-41
pubmed: 25830423
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2
pubmed: 32033882
Clin Physiol Funct Imaging. 2019 Jan;39(1):93-102
pubmed: 30168241
J Am Geriatr Soc. 2014 Feb;62(2):253-60
pubmed: 24428349
J Am Med Dir Assoc. 2017 Jun 1;18(6):553.e1-553.e16
pubmed: 28549707
J Am Coll Cardiol. 2012 Dec 18;60(24):2564-603
pubmed: 23182124
Cochrane Database Syst Rev. 2018 Feb 02;2:CD012786
pubmed: 29394453
Geriatr Gerontol Int. 2017 Oct;17(10):1642-1647
pubmed: 28261905
Heart. 2011 Jul;97(14):1169-74
pubmed: 21561899
Am J Cardiol. 1992 May 15;69(16):1259-64
pubmed: 1585856
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):251-258
pubmed: 27896949
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
Am J Cardiol. 2016 Apr 15;117(8):1355-60
pubmed: 26949037
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Sci Rep. 2017 Jun 9;7(1):3171
pubmed: 28600505
PLoS One. 2014 Nov 18;9(11):e112718
pubmed: 25405866
Circulation. 2011 Nov 29;124(22):2458-73
pubmed: 22052934
J Vasc Surg. 2017 May;65(5):1390-1397
pubmed: 27986478
PLoS One. 2010 May 26;5(5):e10805
pubmed: 22421977
Age Ageing. 2011 Jan;40(1):78-85
pubmed: 20846961
J Am Med Dir Assoc. 2015 Mar;16(3):247-52
pubmed: 25548028
J Bone Miner Metab. 2020 Mar;38(2):161-171
pubmed: 31494773
Diabetol Int. 2020 Jul 24;11(3):165-223
pubmed: 32802702
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
ESC Heart Fail. 2017 Nov;4(4):492-498
pubmed: 29154428
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Arterioscler Thromb Vasc Biol. 2016 May;36(5):1016-21
pubmed: 27034471
Obes Res Clin Pract. 2013 Jul-Aug;7(4):e301-7
pubmed: 24306159
Mayo Clin Proc. 2011 Sep;86(9):857-64
pubmed: 21878597
Open Heart. 2016 Jun 10;3(1):e000406
pubmed: 27335655
Int J Mol Sci. 2020 May 20;21(10):
pubmed: 32443765
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Arch Pharm Res. 2018 Jan;41(1):14-29
pubmed: 29177585
Eur J Heart Fail. 2015 Apr;17(4):424-33
pubmed: 25704364
Clin Nutr. 2021 Apr;40(4):1613-1620
pubmed: 33752149
J Atheroscler Thromb. 2013;20(8):655-60
pubmed: 23892528
Asia Pac J Clin Nutr. 2011;20(4):551-6
pubmed: 22094840
Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1130-1135
pubmed: 29170061
Endocrine. 2015 Nov;50(2):424-33
pubmed: 25862070
Nutr Metab Cardiovasc Dis. 2019 Jul;29(7):718-727
pubmed: 31151882
J Am Med Dir Assoc. 2013 Aug;14(8):585-92
pubmed: 23537893
Diabetes Technol Ther. 2013 Sep;15(9):768-75
pubmed: 23789632
Cardiovasc Drugs Ther. 2010 Feb;24(1):77-83
pubmed: 20352313
J Obes. 2019 Mar 6;2019:8031705
pubmed: 30956817
Circulation. 2016 May 17;133(20):1916-26
pubmed: 27006480
Eur J Cardiovasc Prev Rehabil. 2010 Apr;17(2):230-4
pubmed: 20051870
Curr Opin Clin Nutr Metab Care. 2010 Jan;13(1):1-7
pubmed: 19915458